Pharmaceutical giant Pfizer on Wednesday said that its COVID-19 vaccine candidate was found to be 95 per cent effective in the final analysis of the Phase 3 trial, adding it had the required two-months of safety data and would apply for emergency US authorization within days. The drugmaker said the efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.
NDTV is one of the leaders in the production and broadcasting of un-biased and comprehensive news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.
Subscribe for more videos: https://www.youtube.com/user/ndtv?sub_confirmation=1
Like us on Facebook: https://www.facebook.com/ndtv
Follow us on Twitter: https://twitter.com/ndtv
Download the NDTV Apps: http://www.ndtv.com/page/apps
Watch more videos: http://www.ndtv.com/video?yt
NDTV is one of the leaders in the production and broadcasting of un-biased and comprehensive news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.
Subscribe for more videos: https://www.youtube.com/user/ndtv?sub_confirmation=1
Like us on Facebook: https://www.facebook.com/ndtv
Follow us on Twitter: https://twitter.com/ndtv
Download the NDTV Apps: http://www.ndtv.com/page/apps
Watch more videos: http://www.ndtv.com/video?yt
- Category
- Asia
- Tags
- NDTV 24x7, Pfizer Vaccine, Coronavirus
Sign in or sign up to post comments.
Be the first to comment